For the subset of 23 deceased BRCA1/2 carriers, only 4 had prior clinical testing and the percentage with syndromic cancer diagnoses was 47.8%, which is similar to published observations of clinically ascertained cases.3 This evidence concerns the gene BRCA1 and cancer.